LNTH vs NEOG vs RTGN Stock Comparison

Lantheus Holdings, Neogen and RetinalGenix Technologies Prices as of Oct 27, 2026 Peers: Industry group
LNTH Lantheus Holdings, Inc.
$100.15 +0.4% 1M +72.3% 1Y
Market cap
$6.53B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.65B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

10 decided of 12

Lantheus Holdings leads on 8 of the 12 questions below (Lantheus Holdings 8, Neogen 1, RetinalGenix Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionLNTHNEOGRTGNLeader
Larger companyMarket capitalisation $6.53B $2.65B $75.19M LNTH
Cheaper on earningsLower P/E, profitable companies only 23.7x -47.3x -35.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.4x 39.0x — LNTH
Faster revenue growthRevenue growth, trailing twelve months +2.3% -0.3% — LNTH
More profitableNet margin, trailing twelve months 17.7% -6.3% — LNTH
Better return on capitalReturn on invested capital 12.5% -0.2% — LNTH
Less leveragedLower net debt / EBITDA -0.1x 5.4x — LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% — –
Better 1-year returnPrice return, last 12 months +72.3% +100.8% +2.0% NEOG
Better 5-year returnAnnualised price return, 5 years +34.4%/yr -21.4%/yr — LNTH
Less volatileAnnualised volatility, 1 year 32.3% 55.6% 25.5% RTGN
Higher overall scoreMean of the five percentile scores vs peers 80/100 58/100 37/100 LNTH

Percentile Scorecard

LNTHNEOGRTGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLNTHNEOGRTGN
Valuation 80 #46 of 227 71 #66 of 227 62 #86 of 227
Growth 63 #82 of 219 50 #110 of 219 56 #96 of 219
Profitability 94 #13 of 206 62 #79 of 206 –
Financial Health 69 #74 of 238 46 #128 of 238 0 #237 of 238
Shareholder Returns 93 #11 of 134 58 #57 of 134 28 #97 of 134
Overall 80 58 37
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • RTGN ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLNTHNEOGRTGNSPY
1 month +0.4%-9.4%0.0% -0.2%
3 months -2.4%+35.7%-0.2% +3.9%
6 months +19.9%+33.5%+24.7% +8.2%
Year to date +50.5%+78.4%+24.7% +12.9%
1 year +72.3%+100.8%+2.0% +12.3%
3 years +49.9%-18.6%-11.1% +87.4%
3 years, per year +14.4%-6.6%-3.9% +23.3%
5 years +337.5%-69.9%— +67.9%
5 years, per year +34.4%-21.4%— +10.9%
10 years +1,092.3%-35.8%— +261.1%
10 years, per year +28.1%-4.3%— +13.7%

Risk

MeasureLNTHNEOGRTGNSPY
Volatility, 1Y 32.3%55.6%25.5% 12.7%
Downside volatility, 1Y 27.5%46.5%— 12.7%
Beta vs S&P 500, 1Y 0.591.45-0.04 1.00
Return / volatility, 1Y 2.241.810.08 0.97
Max drawdown, 5Y -59.5%-90.6%-92.0% -25.4%
From 52-week high -9.7%-10.8%-0.2% -1.2%
52-week high $110.94$13.98$4.00 $779.14
52-week low $50.69$5.41$3.20 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLNTHNEOGRTGN
P/E now vs peer median 23.7xmedian 29.6x -48.5xmedian 29.6x -35.9xmedian 29.6x
P/S now vs peer median 4.2xmedian 2.9x 3.1xmedian 2.9x —median 2.9x
EV/EBITDA now vs peer median 16.5xmedian 17.4x 30.0xmedian 17.4x —median 17.4x
P/FCF now vs peer median 16.9xmedian 22.3x 54.7xmedian 22.3x -157.3xmedian 22.3x
P/B now vs peer median 5.0xmedian 2.3x 1.3xmedian 2.3x -28.5xmedian 2.3x
PEG now vs peer median 0.22median 1.04 1.73median 1.04 -1.63median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLNTHNEOGRTGN
Revenue $1.56B $883.99M –
Gross profit $936.02M $418.98M –
Operating income $302.34M -$7.38M –
Net income $275.31M -$56.10M -$2.09M
Free cash flow $387.83M $49.80M -$477.94K
R&D $173.09M $19.76M $238.87K
EPS (diluted) $4.08 $-0.26 $-0.11
Cash & equivalents $593.30M $172.00M $27.23K
Total debt $571.05M $774.20M $245.00K
Shares (diluted) 67.52M 218.10M 18.81M
Enterprise value $4.69B $1.99B $75.14M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLNTHNEOGRTGN
P/E 23.7x -48.5x -35.9x
P/FCF 16.9x 54.7x -157.3x
P/Operating cash flow 15.8x 31.9x -157.3x
P/S 4.2x 3.1x –
P/B 5.0x 1.3x -28.5x
P/Tangible book 10.5x 3.4x -28.5x
EV/EBITDA 16.5x 30.0x –
EV/EBIT 21.5x -450.7x –
EV/Revenue 4.2x 3.8x –
EV/FCF 16.8x 66.8x -157.4x
EV/Operating cash flow 15.8x 39.0x -157.4x
PEG (3Y EPS CAGR) 0.22 1.73 -1.63

Growth

14 metrics
MetricLNTHNEOGRTGN
Revenue growth (1Y) 2.3% -0.3% –
Revenue CAGR (3Y) 11.4% -1.3% –
Gross profit growth (1Y) -3.4% 1.8% –
Gross profit CAGR (3Y) 16.3% -3.1% –
Operating income growth (1Y) -30.9% 99.3% –
Operating income CAGR (3Y) 118.8% -29.0% –
Net income growth (1Y) 1.6% 94.6% 24.0%
Net income CAGR (3Y) 102.1% -28.3% 19.7%
EPS growth (1Y) 5.8% 94.6% 25.9%
EPS CAGR (3Y) 105.5% -28.0% 22.0%
Operating cash flow growth (1Y) -21.7% -1.9% 37.1%
Operating cash flow CAGR (3Y) 14.5% 2.9% -17.6%
Free cash flow growth (1Y) -10.1% 1,631% 37.1%
Free cash flow CAGR (3Y) 103.0% 126.1% -17.6%

Profitability

14 metrics
MetricLNTHNEOGRTGN
Gross margin 60.1% 47.4% –
EBITDA margin 25.4% 12.5% –
Operating margin 19.4% -0.8% –
Pretax margin 23.3% -7.7% –
Net margin 17.7% -6.3% –
FCF margin 24.9% 5.6% –
Operating cash flow margin 26.5% 9.6% –
Return on equity 21.8% -2.7% –
Return on assets 11.6% -1.7% –
Return on invested capital 12.5% -0.2% –
Return on capital employed 14.8% -0.2% –
Asset turnover 0.7x 0.3x –
Cash conversion (OCF / net income) 1.5x -1.5x 0.2x
Stock comp / revenue 5.0% 1.3% –

Financial Health

11 metrics
MetricLNTHNEOGRTGN
Debt / assets 23.6% 23.4% 152.1%
Debt / equity 0.4x 0.4x 0.0x
Net debt / EBITDA -0.1x 5.4x –
Debt / FCF 1.5x 15.5x -0.1x
Liabilities / assets 45.7% 36.8% 8,297%
Equity / assets 54.3% 63.2% -8,197%
Interest coverage 15.3x – –
Current ratio 3.1x 3.9x 0.0x
Quick ratio 2.8x 2.1x 0.0x
Cash ratio 1.8x 1.2x 0.0x
Altman Z-score 5.46 1.52 –

Shareholder Returns

7 metrics
MetricLNTHNEOGRTGN
Dividend yield – – –
Net buyback yield 2.9% -0.1% -0.8%
Shareholder yield 2.9% -0.1% -0.8%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLNTHNEOGRTGN
Forward P/E 17.4xFY2026 39.0xFY2026 –
EPS, next fiscal year $5.76FY2026 $0.32FY2026 –
EPS growth, next FY -5.3%FY2026 0.0%FY2026 –
EPS growth, the year after +4.2% +31.3% –
Revenue, next fiscal year $1.57BFY2026 $847.28MFY2026 –
Revenue growth, next FY +1.8%FY2026 -2.7%FY2026 –
Revenue growth, the year after +12.7% -1.5% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLNTHNEOGRTGN
Held by institutions 100.0% 100.0% –
Institutions holding 465 315 –
Change in shares held, QoQ +3.4% +1.6% –
Institutions buying 248 151 –
Institutions selling 142 106 –
Buyers to sellers 1.75 1.42 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

LNTHNEOGRTGN
LNTH 1.00 0.08 0.09
NEOG 0.08 1.00 -0.08
RTGN 0.09 -0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, LNTH, NEOG and RTGN?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Lantheus Holdings (LNTH) $6.53B, Neogen (NEOG) $2.65B, RetinalGenix Technologies (RTGN) $75.19M.

Which company is growing faster?

Lantheus Holdings (LNTH) grew revenue fastest over the trailing twelve months: Lantheus Holdings (LNTH) +2.3%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Lantheus Holdings (LNTH) 17.7%, Neogen (NEOG) -6.3%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Lantheus Holdings (LNTH) +72.3%, Neogen (NEOG) +100.8%, RetinalGenix Technologies (RTGN) +2.0%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Lantheus Holdings (LNTH) +34.4%/yr, Neogen (NEOG) -21.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, RetinalGenix Technologies (RTGN) has been the steadiest (Lantheus Holdings (LNTH) 32.3%, Neogen (NEOG) 55.6%, RetinalGenix Technologies (RTGN) 25.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, LNTH, NEOG and RTGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.